Efficacy and safety of once-weekly semaglutide in elderly subjects with type 2 diabetes: post hoc analysis of SUSTAIN 1-5 trials

被引：0
|
作者：
Warren, M. [1 ]
Chaykin, L. [2 ]
Trachtenbarg, D. [3 ]
Nayak, G. [4 ]
Wijayasinghe, N. [4 ]
Cariou, B. [5 ]
机构：
[1] Phys East, Greenville, NC USA
[2] Meridien Res, Bradenton, FL USA
[3] Univ Illinois, Coll Med Peoria, Peoria, IL USA
[4] Novo Nordisk AS, Soborg, Denmark
[5] CHU Nantes, Inst Thorax, Nantes, France
来源：
DIABETOLOGIA | 2017年 / 60卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
819
引用
收藏
页码：S378 / S379
页数：2
相关论文
共 50 条
  • [1] Efficacy and safety of once-weekly semaglutide in Japanese individuals with type 2 diabetes in the SUSTAIN 1, 2, 5 and 9 trials: Post-hoc analysis
    Araki, Eiichi
    Harashima, Shinichi
    Nishida, Tomoyuki
    Nakamura, Jiro
    [J]. JOURNAL OF DIABETES INVESTIGATION, 2022, : 1971 - 1980
  • [2] Efficacy and safety of once-weekly semaglutide monotherapy vs placebo in subjects with Type 2 diabetes (SUSTAIN 1)
    Sorli, C.
    Harashima, S-I
    Tsoukas, G.
    Unger, J.
    Karsbol, J. D.
    Bain, S.
    [J]. DIABETIC MEDICINE, 2017, 34 : 145 - 145
  • [3] Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in subjects with type 2 diabetes (SUSTAIN 1)
    Harashima, Shin-ichi
    Sorli, Christopher
    Tsoukas, George
    Unger, Jeffrey
    Karsbol, Julie Derving
    Hansen, Thomas
    Bain, Stephen
    [J]. DIABETES RESEARCH AND CLINICAL PRACTICE, 2016, 120 : S121 - S121
  • [4] Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in subjects with type 2 diabetes (SUSTAIN 1)
    Sorli, C.
    Harashima, S. -I.
    Tsoukas, G.
    Unger, J.
    Karsbol, J. Derving
    Hansen, T.
    Bain, S.
    [J]. DIABETOLOGIA, 2016, 59 : S364 - S364
  • [5] Effect of once-weekly semaglutide on insulin use in subjects with type 2 diabetes: a post hoc analysis of SUSTAIN 6
    Seufert, J.
    Desouza, C.
    Kirk, A. R.
    Lawson, J.
    Lingvay, I.
    Sondergaard, A. L.
    Bain, S. C.
    [J]. DIABETOLOGIA, 2021, 64 (SUPPL 1) : 251 - 252
  • [6] Efficacy and safety of semaglutide in subjects with type 2 diabetes by race and ethnicity: a post hoc analysis of the SUSTAIN trials
    Desouza, C.
    Garg, S.
    Cariou, B.
    Furberg, J. K.
    Navarria, A.
    Nayak, G.
    Fonseca, V.
    [J]. DIABETOLOGIA, 2018, 61 : S369 - S370
  • [7] Efficacy and safety of semaglutide in elderly subjects with type 2 diabetes: a post hoc analysis of the SUSTAIN 7 trial
    Aroda, V. R.
    Sugimoto, D.
    Trachtenbarg, D.
    Warren, M.
    Navarria, A.
    Nayak, G.
    Nielsen, M. Abildlund
    Woo, V.
    [J]. DIABETOLOGIA, 2018, 61 : S367 - S367
  • [8] Efficacy and Safety of Once-Weekly Semaglutide vs. Exenatide ER in Subjects with Type 2 Diabetes (SUSTAIN 3)
    Ahmann, Andrew J.
    Capehorn, Matthew
    Charpentier, Guillaume
    Dotta, Francesco
    Henkel, Elena
    Lingvay, Ildiko
    Holst, Anders Gaarsdal
    Chang, Denise
    Aroda, Vanita R.
    [J]. DIABETES, 2016, 65 : A49 - A49
  • [9] Efficacy and safety of once-weekly semaglutide low dose 0.5 mg vs once-weekly dulaglutide high dose 1.5 mg in type 2 diabetes: a post hoc analysis of SUSTAIN 7
    Pratley, R. E.
    Aroda, V. R.
    Gondolf, T.
    Hansen, T.
    Lingvay, I.
    Ludemann, J.
    Skjoth, T. V.
    Viljoen, A.
    [J]. DIABETOLOGIA, 2019, 62 : S374 - S374
  • [10] Efficacy and safety of once-weekly semaglutide for the treatment of type 2 diabetes
    Tan, Xueying
    Cao, Xiaojing
    Zhou, Minzhi
    Zou, Ping
    Hu, Jingbo
    [J]. EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2017, 26 (09) : 1083 - 1089
12345